Martin C Michel
Overview
Explore the profile of Martin C Michel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
328
Citations
4904
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Oelke M, Abt S, Becher K, Dreikorn K, Madersbacher S, Magistro G, et al.
Urologie
. 2023 Jul;
62(8):805-817.
PMID: 37401972
Background: Lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH; in German guidelines: benign prostatic syndrome [BPS]) is the most frequent urological disease in men and can result...
22.
Muderrisoglu A, Sakul A, Murgas S, de la Rosette J, Michel M
Front Pharmacol
. 2023 Apr;
14:1144470.
PMID: 37063295
Pelvic hypoperfusion caused by atherosclerosis has been proposed as a cause of lower urinary tract dysfunction including overactive bladder syndrome (OAB). Limited data indicate that OAB patients with concomitant diabetes...
23.
Kayki-Mutlu G, Aksoyalp Z, Wojnowski L, Michel M
Naunyn Schmiedebergs Arch Pharmacol
. 2023 Mar;
396(8):1619-1632.
PMID: 36951997
While new drug approvals by the U.S. Food and Drug Administration (FDA) had remained stable or even increased in the first 2 years of the COVID-19 pandemic, the 37 newly...
24.
Michel M, Cardozo L, Chermansky C, Cruz F, Igawa Y, Lee K, et al.
Pharmacol Rev
. 2023 Mar;
75(4):554-674.
PMID: 36918261
Overactive bladder syndrome with and without urinary incontinence and related conditions, signs, and disorders such as detrusor overactivity, neurogenic lower urinary tract dysfunction, underactive bladder, stress urinary incontinence, and nocturia...
25.
Erdogan B, Michel M, Matthes J, Castaneda T, Christen U, Arioglu-Inan E, et al.
Front Pharmacol
. 2023 Mar;
14:1118730.
PMID: 36891264
Diabetes often leads to lower urinary tract dysfunction. The most frequently assessed parameter of urinary bladder dysfunction in animal models of diabetes is an enlargement of the bladder, which is...
26.
Michel M, Heemann U, de la Rosette J
Front Pharmacol
. 2022 Dec;
13:1081074.
PMID: 36582525
While animal studies have suggested an association between the presence of hypertension and the presence and/or severity of overactive bladder syndrome (OAB) symptoms, little clinical data is available. We have...
27.
Stoevelaar H, Bahl A, Helsen N, Michels N, Smets L, Speakman M, et al.
J Eur CME
. 2022 Dec;
11(1):2153438.
PMID: 36465494
The PinPoint Case Platform (PPCP) offers independent online case-based CME. To align with personal learning needs, a functionality of needs assessments ("QuickScan") was developed, directing users to follow personalised case...
28.
Storr M, Weigmann H, Landes S, Michel M
J Clin Med
. 2022 Nov;
11(21).
PMID: 36362589
Functional gastrointestinal disorders (FGIDs), including irritable bowel syndrome (IBS), are frequently handled by self-management with over-the-counter (OTC) products such as hyoscine butylbromide (HBB), alone or in combination with paracetamol, and...
29.
Kayki-Mutlu G, Aksoyalp Z, Wojnowski L, Michel M
Naunyn Schmiedebergs Arch Pharmacol
. 2022 Nov;
396(2):383.
PMID: 36335284
No abstract available.
30.
Michel M
Neurourol Urodyn
. 2022 Nov;
42(1):33-39.
PMID: 36321795
Aims: β -adrenoceptors (ARs) are an important drug target for the treatment of overactive bladder syndrome (OAB) and are under investigation for other indications. The human β -AR gene is...